Successful clinical trials [54,55,56] confirmed PD-1 as the most effective target and today PD-1/PD-L1 checkpoint blockade therapy is part of the standard therapy for multiple malignancies, such as Hodgkin’s lymphoma and melanoma. The gene discussed is PDCD1; the disease is Hodgkins lymphoma.